Click Here to Register »

2018 Agenda

  • 8:00 am

  • Registration & Breakfast

  • 8:45 am

  • Co-chairs' Opening Remarks


    James Gulley, MD, PhD

    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline


  • Discovery & Preclinical Plenary Session

  • 9:00 am

  • NK Cell CARs


    Dario Campana, MD, PhD

    Mrs Lee Kong Chian Chair in Advanced Cellular Therapy; Professor, Department of Pediatrics; Director, Division of Immunopathology and Cell Therapy
    National University of Singapore


  • Target Discovery for CAR-Ts and TCRs


    Laura Johnson, PhD

    Senior Director, Head Translational Medicine, Oncology Cell Therapy, GlaxoSmithKline


  • Morning Networking Break


  • Combination IDO1 and PD-1 inhibition in Metastatic Melanoma


    Hiroomi Tada, MD, PhD

    Executive Director, Immuno-Oncology Development, Incyte


  • Early Clinical Data: Dual Targeting PDL1 and TGF Beta


    Julius Strauss, MD

    Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute


  • Investor Relations in Immunotherapy Plenary Session

  • 11:20 am

  • Plenary Keynote: Evaluation and Forecast of the IO Space


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi


  • Venture Capitalist Perspective on the IO Landscape


    Bruce Booth, DPhil

    Partner, Atlas Venture


  • Lunch


  • Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?

    Moderator:

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline

    Panelists:


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi


    Bruce Booth, DPhil

    Partner, Atlas Venture


    Ali Behbahani, MD

    Partner, New Enterprise Associates


    Simeon George, MD

    Partner, SR One Ltd


  • Translational Science and Biomarkers Plenary Session

  • 2:10 pm

  • The Role of Antibody Isotypes for Agonist Antibodies - ICOS


    Patrick Mayes, PhD

    Director & Early Development Leader, GlaxoSmithKline


  • Tumor Mutation Burden

    Christine Ward
    Christine K Ward, PhD

    Director and Pharmacodiagnostics Lead – HQ Medical Oncology, Bristol-Myers Squibb


  • Immune Suppression in The Tumor Micro-environment: The Adenosine Pathway


    Ian McCaffery, PhD

    VP, Translational Science, Corvus Pharmaceuticals


  • MORPHEUS Novel CIT Platform to Address Multiple Combinations


    William Grossman, MD, PhD

    Global Development Leader, Cancer Immunotherapy Combinations, Genentech


  • Afternoon Networking Break


  • Update on Cancer Vaccination and Biomarkers of Response

    Lisa Butterfield
    Lisa Butterfield, PhD

    Professor of Medicine, Surgery and Immunology Director, UPCI Immunologic Monitoring and Cellular Products Laboratory / President, University of Pittsburgh / Society for Immunotherapy of Cancer (SITC)


  • Using TC Clonality Detecting Minimal Residual Disease


    Lanny Kirsch, MD

    SVP, Translational Medicine, Adaptive Biotechnologies


  • Use of Imaging Biomarkers for Immunotherapy


    Ron Korn, MD, PhD

    Founder, Chairman and Chief Medical Officer, Imaging Endpoints


  • Neoantigen Approaches for Biomarkers


  • Emerging Concepts for the Detection of Minimal Residual Disease using Liquid Biopsies


    Jonathan Wan
    MD, PhD Student
    Cancer Research UK Cambridge Institute

  • 6:30 pm

  • End of Day One

2018 Agenda

  • 8:15 am

  • Registration & Breakfast

  • 8:45 am

  • Co-chairs' Opening Remarks


    James Gulley, MD, PhD

    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline


  • New Trends & Collaborations Plenary Session

  • 9:00 am

  • The BioCentury Report on Industry Trends


    Simone Fishburn, PhD

    Editor, BioCentury Innovations


  • The Endpoint News Report


    John D Carroll

    Editor-in-Chief, Endpoints News


  • Morning Networking Break


  • Cancer Moonshot Progress


    Greg Simon, JD

    President, Biden Cancer Initiative and Former Executive Director, Former White House Cancer Task Force  


  • Immuno-Oncology Progress in China


    Ji Li, PhD

    EVP, Global Head of Business Development, BeiGene


  • Clinical Trial Collaborations in IO


  • IO Emerging Technologies & Innovative Solutions Plenary Session

    This plenary will showcase companies that have technologies and solutions that will help stakeholders in the IO field advance developments to provide treatment for cancer patients.

  • 11:00 am


  • Ji Li, PhD

    EVP, Global Head of Business Development, BeiGene

    Additional Companies TBD

  • 12:00 pm

  • Lunch

  • 1:00 pm

  • Translational Science and Biomarkers Plenary Session Part II

  • 2:30 pm
    - 6:30 pm

    • 2:30 pm

      Business Aspects Plenary Session

      Summary of IO Deals


      Jeff Bockman, PhD

      Principal, SVP, Oncology Practice Head, Defined Health

       

      Large Pharma Perspective on IO Licensing Technology

      Peter-Joern Halle
      Joern-Peter Halle, PhD

      SVP, Head of External Innovation and Head of TIP Immuno-Oncology / Biopharma, Global Research & Development, EMD Serono

       

      Panel: Talent Management for IO

      Moderator:


      Cissy Young, PhD, MBA

      Executive Director, Russell Reynolds Associates

      Panelists:


      Jasmine Ferrer, DPhil

      Sr Client Partner, Biotech & Pharma Sector, Korn Ferry International


      Adam Millinger

      Founding Partner, ProMotion Career Management

    • 2:30 pm

      Clinical Operations for IO Trials Plenary Session

      As Immuno-Oncology clinical trials have exceptionally unique requirements, IO360 is featuring a specialized plenary on the building blocks of clinical trial design and operations.

      Led by:


      Andy Lee
      SVP, Head of Global Clinical Trial Operations, Merck

       

      Talks and additional speakers to be announced shortly.

  • 6:30 pm

  • Networking Cocktail Reception

2018 Agenda

  • 8:15 am

  • Registration & Breakfast

  • 8:45 am

  • Co-chairs' Opening Remarks


    James Gulley, MD, PhD

    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline


  • Clinical Aspects Plenary Session

  • 9:00 am

  • Balancing Benefit and Toxicity From Immunotherapeutics: How to Make Recommendations to Patients


    Jeffrey Weber, MD, PhD

    Deputy Director, Laura and Isaac Perlmutter Cancer Center, Co-Director, Melanoma Program & Head of Experimental Therapeutics, NYU Langone Medical Center


  • Maintenance Therapy in NSCLC


    Naiyer Rizvi, MD

    Director, Thoracic Oncology & Immunotherapeutics in Medical Oncology, NY Presbyterian / Columbia University Medical Center


  • Morning Networking Break


  • Keytruda in Combo with Chemo in NSCLC


    Corey Langer, MD, FACP

    Director, Thoracic Oncology; Professor of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania

  • Learning from Kymriah - From Pivotal Trials to Launch

    David Lebwohl
    David Lebwohl, MD

    SVP & Franchise Global Program Head, CAR-T, Promacta and SEG101 GPTs, Oncology Global Development, Global Drug Development, Novartis Pharmaceuticals


  • Update on Tecentriq (Atezolizumab) in Bladder Cancer


  • The Role of PDL1 on Survival


  • Changing Treatment Landscape in NSCLC


  • Lunch


  • Pembrolizumab as a Broad Spectrum Anticancer Therapy Both as Mono and Combination Therapy


    Roy Baynes, MD, PhD

    SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories


  • Differences in Long Term Benefit Between Classes of Checkpoint Modulators


  • Trout Group Situation Room

    2017 trout group

  • 3:00 pm

  • Executive Fireside Chat

    Moderator:

    Jonathan Fassberg
    Jonathan Fassberg

    CEO, Trout Group


  • The Investor Lifecycle - How to Maneuver at Each Stage of Financing from Seed to Public Market

    Moderator:

    Neil Canavan
    Neil Canavan

    Scientific Advisor, Trout Group

    Panelists:

    Ting Jia
    Ting Jia, PhD

    Managing Director, Hillhouse Capital Management

    Joseph Sum
    Joseph Sum

    Director of Research, ECOR1 Capital


  • CEO Panel: Raising Money in the Current Climate

    Moderator:

    Jonathan Fassberg
    Jonathan Fassberg

    CEO, Trout Group

    Panelist:

    Gary Menzel
    Garry Menzel, PhD, MBA

    CEO, TCR² Therapeutics


  • IO CEO Fireside Chats

    Moderator:

    Peter Rahmer
    Peter Rahmer

    Managing Director, Trout Group

    Fireside Guests:

    Sean McCarthy
    Sean McCarthy, DPhil

    President and Chief Executive Officer, CytomX Therapeutics

    Stephen Yoder
    Stephen S Yoder, JD

    President & CEO, Pieris Pharmaceuticals

  • 5:00 pm

  • Conference Concludes